Search Site

Trends banner

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

UAB net profit up by 50% for H1

Total assets increase by 11 percent.

TSMC Q2 profit up 60%

TSMC is the world's largest contract maker of chips.

Glaxo buys Bellus for US$2bn

A Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026. (AFP)
  • GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, the British drugmaker said in a statement.
  • Chronic cough is defined as a persistent cough that lasts more than eight weeks and affects an estimated 28 million people worldwide.

LONDON, UK – British drugmaker GlaxoSmithKline on Tuesday announced the purchase of Canadian chronic cough treatment specialist Bellus for US$2 billion.

It comes after GSK, led by chief executive Emma Walmsley, demerged its consumer healthcare unit Haleon last year, leaving the group to focus on drugs.

GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, it said in a statement.

Chronic cough, defined as a persistent cough that lasts more than eight weeks, affects an estimated 28 million people worldwide.

While there are no approved medicines in the European Union or United States, a Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026.

“Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues,” GSK’s chief commercial officer Luke Miels said in the statement.

“Camlipixant… has the potential to be a best-in-class treatment with significant sales potential,” he added.